New data demonstrate stability of ReNeuron’s lead stem cell line in scale-up conditions

New data demonstrate stability of ReNeuron’s lead stem cell line in scale-up conditions

ReNeuron Group plc announces that its academic collaborators are presenting new data regarding the stability of the Company's lead CTX stem cell line in large-scale manufacturing conditions. The first clinical application for the CTX cell line is ReNeuron's ReN001 stem cell therapy for disabled stroke patients, currently in Phase I clinical development.

Professor Mike Hoare, Co-Director of The Advanced Centre for Biochemical Engineering at University College London (UCL), will present the results at the Scale-Up and Manufacturing of Cell-Based Therapies conference in San Diego, US, on 11-13 January 2012. The UCL team conducted studies with a number of cell candidates, including ReNeuron's CTX cell line.  The results show that the CTX cells retained their morphology and growth characteristics when exposed to the levels of shear and centrifugal stresses that could be experienced in future large-scale manufacture of the cells for widespread clinical use.

The studies were conducted with the support of a grant from the UK Government's Technology Strategy Board and form part of a larger bioprocessing collaboration under the grant involving ReNeuron, UCL, Nottingham Trent University, LGC and others.

Dr John Sinden, Chief Scientific Officer of ReNeuron, commented: "These new research results demonstrate the robust nature of ReNeuron's CTX cell line when subjected to manufacturing scale-up stresses and thus the potential of this cell line to form the basis of a cell-based therapeutic product for wide-scale clinical application. The ability to utilise ReNeuron's proprietary cell expansion technologies to readily manufacture our cell products at scale has always been a primary element in our product development strategy and one that we believe will pay off for the Company when we seek to license our therapies to commercial development partners in due course."

No Comments

Post a Comment